Broadly Neutralizing Aptamers to SARS-CoV-2: A Diverse Panel of Modified DNA Antiviral Agents

Investigators report the identification of modified DNA-based aptamers that selectively bound to the S1, S2, or receptor-binding domain of SARS-CoV-2 spike protein.